Amphastar Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Amphastar Pharmaceuticals (AMPH) VP Rong Zhou plans to sell 10,000 shares, including 10,000 from an option exercise and smaller lots from the ESPP. The sale is under Rule 144, with UBS Financial Services acting as attorney-in-fact. The largest block is 10,000 shares.
Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
Amphastar Pharmaceuticals (AMPH) insider Floyd Petersen plans to sell 47,101 shares, worth $989,121, via UBS. The shares were acquired through option exercise, with the sale proposed for August 18, 2026. Amphastar has 44.1 million shares outstanding. The sale is under SEC Rule 144, which governs insider share sales.
Over the past 7 days, alphai's AI scored 1 news story mentioning AMPH (Amphastar Pharmaceuticals, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent AMPH coverage spans earnings, financial news and regulation.
In the last 30 days, AMPH insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($237K). The most active reporter was Zhou Rong, SENIOR EVP, PRODUCTION CENTER, with 1 filing.
The filing signals potential new supply of AMPH shares, which could modestly pressure the stock price.
Strong earnings beat drives significant short‑term rally.
The filing indicates a near-term, pre-planned insider sale that can add incremental float and weigh on sentiment, though the disclosed size is modest versus shares outstanding.
Earnings were received positively, with both EPS and revenue beats supporting a modest upward reaction.
Near-term earnings pressure risk from IMS remediation costs, partially offset by gross margin expansion from higher-margin launches and continued full-year sales growth guidance.
alphai scores every news story that mentions AMPH with an AI model for sentiment and relevance, and aggregates insider trades from Amphastar Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amphastar Pharmaceuticals (AMPH) VP Rong Zhou plans to sell 10,000 shares, including 10,000 from an option exercise and smaller lots from the ESPP. The sale is under Rule 144, with UBS Financial Services acting as attorney-in-fact. The largest block is 10,000 shares.
1 min readBristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
3 min readAmphastar Pharmaceuticals (AMPH) insider Floyd Petersen plans to sell 47,101 shares, worth $989,121, via UBS. The shares were acquired through option exercise, with the sale proposed for August 18, 2026. Amphastar has 44.1 million shares outstanding. The sale is under SEC Rule 144, which governs insider share sales.
2 min readA peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;
6 min readAmphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.
6 min readAmphastar Pharmaceuticals (AMPH) reported Q2 revenue of $183.9M vs $180.3M estimates and adjusted EPS of $0.91 vs $0.61, citing demand for BAQSIMI and Primatene MIST and the launch of ipratropium bromide. Analysts asked about R&D/SG&A, IMS FDA warning letter, business development, and margins for insulin aspart biosimilar.
7 min readPRINS RICHARD K sold 7,973 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $20.30 ($0.16M total) on 2026-08-11.
2 min readAmphastar Pharmaceuticals said it expects higher operating expenses in coming quarters due to remediation costs at its IMS facility, partly offset by shifting capital spending from other sites. Management highlighted progress in its development pipeline, including an insulin aspart biosimilar targeted for commercialization in 2027, and expects mid- to high-single-digit sales growth despite competition.
5 min readAmphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.
4 min readAmphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 - Net revenues of $183.9 million for the three months ended June 30, 2026 - GAAP net income of $30.3 million, or $0.67 per share, for the second quarter - Adjusted no
7 min read
